Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galapagos N.V. (NASDAQ: GLPG).

Full DD Report for GLPG

You must become a subscriber to view this report.


Recent News from (NASDAQ: GLPG)

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Mechelen, Belgium; 31 October 2018; 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). PINTA is a randomized, double-blind, placebo-controlled Ph...
Source: GlobeNewswire
Date: October, 31 2018 17:02
Gilead: The Good, The 'Meh' And The Ugly
Q3 is 'meh' and a downgrade and second 'meh' for filgotinib The title notwithstanding, I'll begin with the 'meh' or neutral news. Gilead ( GILD ) reported Q3 on Thursday. It showed pre-tax income of $2.7 B, sharply down yoy from $3.7 B. Results were flattered by $305 MM in "other" income...
Source: SeekingAlpha
Date: October, 29 2018 15:51
Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini - New Research Emphasizes Economic Growth
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICON PLC (NASDAQ:ICLR), Robert Half International Inc. (NYSE:RHI), Center...
Source: GlobeNewswire
Date: October, 29 2018 07:25
Proteostasis up 12% premarket following Galapagos CF data
Proteostasis Therapeutics (NYSE: PTI ) is up  12%  premarket on light volume in apparent reaction to the release of preliminary data from a Phase 1b clinical trial, FALCON , evaluating Galapagos NV's (NASDAQ: GLPG ) triplet therapy for cystic fibrosis (CF), GLPG2451, GLPG2222 an...
Source: SeekingAlpha
Date: October, 25 2018 08:13
AbbVie to take over cystic fibrosis program from Galapagos
AbbVie (NYSE: ABBV ) will assume full development and commercial responsibility for the cystic fibrosis (CF) program from collaboration partner Galapagos (NASDAQ: GLPG ). More news on: AbbVie Inc., Galapagos, Vertex Pharmaceuticals Incorporated, Healthcare stocks news, Read more ... ...
Source: SeekingAlpha
Date: October, 25 2018 06:56
Platinum Asset Management Quarterly Report September 30, 2018
Read more ...
Source: SeekingAlpha
Date: October, 25 2018 06:00
Gilead and Galapagos' TORTUGA Phase 2 study of filgotinib in AS achieves primary endpoint
Gilead Sciences (NASDAQ: GILD ) and Galapagos NV (NASDAQ: GLPG ) announces that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ...
Source: SeekingAlpha
Date: September, 06 2018 06:22
GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, a...
Source: GlobeNewswire
Date: September, 06 2018 01:01
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with mo...
Source: Business Wire
Date: September, 06 2018 01:00
Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0895.3695.3596.6594.7987,918
2018-05-1797.6396.6897.6396.2458,018
2017-02-0266.1767.8867.9766.11160,943
2017-02-0166.7067.2467.4066.3087,362
2017-01-3164.0165.1065.3463.69102,236

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1836,06669,14952.1569Short
2018-12-177,47020,60036.2621Short
2018-12-148,92118,82947.3790Short
2018-12-1320,07326,95074.4824Short
2018-12-126,72116,02741.9355Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GLPG.


About Galapagos N.V. (NASDAQ: GLPG)

Logo for Galapagos N.V. (NASDAQ: GLPG)

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.

 

Contact Information

 

 

Current Management

  • Onno van de Stolpe / CEO
  • Guillaume Jetten / CFO
  • Elizabeth Goodwin / IR Manager
  • Raj Parekh / Chairman

Current Share Structure

  • Market Cap: $2,555,535,509 - 05/16/2018
  • Issue and Outstanding: 26,770,747 - 12/31/2012

 


Recent Filings from (NASDAQ: GLPG)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 23 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (NASDAQ: GLPG)

Daily Technical Chart for (NASDAQ: GLPG)


Stay tuned for daily updates and more on (NASDAQ: GLPG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GLPG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GLPG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GLPG and does not buy, sell, or trade any shares of GLPG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/